ロード中...
LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer
PURPOSE: We report that the reactivity of a novel monoclonal antibody LpMab-23 for human cancer-type podoplanin (PDPN) is a predictor for a poor prognosis of tongue cancer. PATIENTS AND METHODS: The association between LpMab-23-recognizing cancer-type PDPN expression and clinical/pathological featur...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5940393/ https://ncbi.nlm.nih.gov/pubmed/29765527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24986 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|